Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1359442rdf:typepubmed:Citationlld:pubmed
pubmed-article:1359442lifeskim:mentionsumls-concept:C0009170lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0025914lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0678812lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0115201lld:lifeskim
pubmed-article:1359442lifeskim:mentionsumls-concept:C0522501lld:lifeskim
pubmed-article:1359442pubmed:issue9lld:pubmed
pubmed-article:1359442pubmed:dateCreated1992-11-27lld:pubmed
pubmed-article:1359442pubmed:abstractTextThe effects of systemic administration (i.p.) of dynorphin A(1-13) on the cocaine-induced behavioural alterations in the mouse were determined by using multi-dimensional behavioural analyses, based upon a capacitance system. A 1.0 mg/kg dose of cocaine did not influence behaviour, while increasing doses to 3-30 mg/kg produced a significant increment in the frequency of behaviour, such as linear locomotion, circling, rearing and grooming. Although a 1.0 mg/kg dose of dynorphin A(1-13) alone produced a significant decrease in grooming behaviour, larger doses (3.0 and 10.0 mg/kg) of the peptide failed to affect different behaviour. The cocaine (3.0 mg/kg)-induced increases in linear locomotion, circling and rearing behaviour were significantly inhibited by dynorphin A(1-13) (10.0 mg/kg). The inhibitory effects of dynorphin A(1-13) (10.0 mg/kg) were antagonized by the opioid antagonist Mr 2266 (5.6 mg/kg). It is thus possible that the systemic administration of dynorphin A(1-13) inhibits different behavioural responses induced by cocaine through the blood-brain barrier, although the instability of amino acid bonds or the relatively large molecular weight of dynorphin A(1-13), may result in the failure to demonstrate opioid activity by the peptide after systemic administration.lld:pubmed
pubmed-article:1359442pubmed:languageenglld:pubmed
pubmed-article:1359442pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:citationSubsetIMlld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1359442pubmed:statusMEDLINElld:pubmed
pubmed-article:1359442pubmed:monthSeplld:pubmed
pubmed-article:1359442pubmed:issn0028-3908lld:pubmed
pubmed-article:1359442pubmed:authorpubmed-author:KamiyaTTlld:pubmed
pubmed-article:1359442pubmed:authorpubmed-author:KameyamaTTlld:pubmed
pubmed-article:1359442pubmed:authorpubmed-author:UkaiMMlld:pubmed
pubmed-article:1359442pubmed:authorpubmed-author:ToyoshiTTlld:pubmed
pubmed-article:1359442pubmed:issnTypePrintlld:pubmed
pubmed-article:1359442pubmed:volume31lld:pubmed
pubmed-article:1359442pubmed:ownerNLMlld:pubmed
pubmed-article:1359442pubmed:authorsCompleteYlld:pubmed
pubmed-article:1359442pubmed:pagination843-9lld:pubmed
pubmed-article:1359442pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:meshHeadingpubmed-meshheading:1359442-...lld:pubmed
pubmed-article:1359442pubmed:year1992lld:pubmed
pubmed-article:1359442pubmed:articleTitleSystemic administration of dynorphin A(1-13) markedly inhibits different behavioural responses induced by cocaine in the mouse.lld:pubmed
pubmed-article:1359442pubmed:affiliationDepartment of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Meijo University, Nagoya, Japan.lld:pubmed
pubmed-article:1359442pubmed:publicationTypeJournal Articlelld:pubmed